



(11) **EP 2 906 684 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 5/0783 ^(2010.01) **C12N 15/00** ^(2006.01)
C12N 15/87 ^(2006.01) **A61K 35/17** ^(2015.01)
C07K 16/28 ^(2006.01)

(48) Corrigendum issued on:
02.09.2020 Bulletin 2020/36

(86) International application number:
PCT/US2013/064384

(45) Date of publication and mention
of the grant of the patent:
22.07.2020 Bulletin 2020/30

(87) International publication number:
WO 2014/059173 (17.04.2014 Gazette 2014/16)

(21) Application number: **13845951.6**

(22) Date of filing: **10.10.2013**

(54) **T CELL MODIFYING COMPOUNDS AND USES THEREOF**

T-ZELL-MODIFIZIERENDE VERBINDUNGEN UND VERWENDUNGEN DAVON
COMPOSÉS MODIFIANT LES LYMPHOCYTES T ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **10.10.2012 US 201261712028 P**

(43) Date of publication of application:
19.08.2015 Bulletin 2015/34

(60) Divisional application:
20183942.0

(73) Proprietor: **Sangamo Therapeutics, Inc.**
Brisbane, CA 94005 (US)

(72) Inventors:
• **GREGORY, Philip D.**
Richmond
California 94804 (US)
• **HOLMES, Michael C.**
Richmond
California 94804 (US)

(74) Representative: **Carpmaels & Ransford LLP**
One Southampton Row
London WC1B 5HA (GB)

(56) References cited:
WO-A2-2008/153742 US-A1- 2011 158 957
US-A1- 2011 158 957

- **BERGER C ET AL: "Adoptive transfer of virus-specific and tumor-specific T cell immunity", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 21, no. 2, 1 April 2009 (2009-04-01), pages 224-232, XP026058400, ISSN: 0952-7915, DOI: 10.1016/J.COI.2009.02.010 [retrieved on 2009-03-21]**
- **H. TORIKAI ET AL: "A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", BLOOD, vol. 119, no. 24, 14 June 2012 (2012-06-14), pages 5697-5705, XP055071623, ISSN: 0006-4971, DOI: 10.1182/blood-2012-01-405365**
- **PADMANEE SHARMA ET AL: "Novel cancer immunotherapy agents with survival benefit: recent successes and next steps", NATURE REVIEWS CANCER, vol. 11, no. 11, 24 October 2011 (2011-10-24), pages 805-812, XP055110127, ISSN: 1474-175X, DOI: 10.1038/nrc3153**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 906 684 B8

- **KALOS MICHAEL ET AL:** "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", 20110810, vol. 3, no. 95, 10 August 2011 (2011-08-10), page 95ra73.1, XP002667262,
- **DREW M. PARDOLL:** "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS CANCER, vol. 12, no. 4, 22 March 2012 (2012-03-22) , pages 252-264, XP055150744, ISSN: 1474-175X, DOI: 10.1038/nrc3239
- **BERGER ET AL.:** 'Adoptive transfer of virus-specific and tumor-specific T cell immunity' CURR OPIN IMMUNOL. vol. 21, no. 2, April 2009, pages 224 - 232, XP026058400
- **TORIKAI ET AL.:** 'A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD 19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR' BLOOD vol. 119, no. 24, 14 June 2012, pages 5697 - 5705, XP055071623